Dec. 31, 2021– Today is the final day of what might be one of the most eventful years in the history of the 340B drug pricing program. Key developments in the 340B world stood out even amid all the news about a global pandemic, a change in leadership in Washington, and an uneasy economic climate. As we wrap up 2021 and look forward to a new year, we are reflecting on some of … [Read more...]
Federal Report Suggests Another Reason To End 340B Orphan Drug Loophole
Oct. 18, 2021– A new federal government report could add momentum to efforts on Capitol Hill to end limitations on 340B price discounts for orphan drugs purchased by certain safety-net hospitals. The report suggests that drug companies might be seeking orphan status for their products to maximize revenues and avoid paying 340B discounts on drugs widely used to treat common … [Read more...]
Seventh Drug Company Told It is Violating 340B Law
Oct. 12, 2021– Eight drug companies have restricted access to discounts to safety-net providers through the 340B drug pricing program on drugs dispensed at community-based pharmacies. Now the government officially has informed all but one of those companies that they are in violation of federal law and must restore the discounted pricing. The most recent recipient of a … [Read more...]
HHS Takes Vital Next Step Toward Ending 340B Pricing Denials
Oct. 1, 2021– The federal government has taken dramatic action to get drug companies to restore 340B pricing for outpatient prescription drugs dispensed by community pharmacies to patients of 340B hospitals. On Sept. 22, the Health Resources & Services Administration (HRSA) sent letters to six drugmakers informing them that the agency is asking the Office of Inspector … [Read more...]
A Healthy Dose of Sunlight for Drug Companies
April 1, 2019— Today is a very good day for safety-net hospitals and the patients in need who rely on them. After nine long years of delay and preparation, the federal government today launched a new secure website. The site will provide hospitals, clinics, and health centers participating in the 340B drug pricing program with information on the maximum amount – or ceiling … [Read more...]
Drug Companies May Owe Medicaid $1.3 Billion in Unpaid Rebates
January 3, 2018—Pharmaceutical companies may have misclassified 885 drugs for Medicaid drug rebate purposes in 2016, with the top 10 in terms of highest total reimbursement accounting for potentially $1.3 billion in lost Medicaid drug rebates, the U.S. Department of Health and Human Services Office of Inspector General (OIG) reports. Four drug manufacturers were responsible for … [Read more...]